The U.S. Food and Drug Administration is replacing animal testing with human-relevant methods, including artificial ...

The FDA has announced plans to phase out animal testing in the development of monoclonal antibodies and other drugs.

FDA has cleared an investigational new drug (IND) application to study switchable chimeric antigen receptor T cell (sCAR-T) therapy (CLBR001 + SWI019) in patients with autoimmune conditions. Patient ...

The FDA laid out a three-year roadmap to phase out animal toxicity testing in drug research. In addition to organoids and lab ...

Findings from the CheckMate 9DW trial support the FDA approval of nivolumab and ipilimumab in unresectable hepatocellular ...

An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with ...

Pluvicto, a prostate cancer drug, has gained expanded approval that triples the number of patients with metastatic disease ...

The FDA has approved an application to initiate a pilot study with Alpha DaRT for patients with recurrent glioblastoma, a ...

The drug manufacturer will no longer study and test danuglipron after a participant in a clinical trial was injured.

The FDA issued a complete response letter for the resubmission of the reproxalap new drug application for the treatment of ...

After reviewing all the data and considering input from regulators, Pfizer decided to discontinue the danuglipron program.